Share price
$74.00
−5.01% intraday
Cytokinetics Shares Drop 5% Even as Company Delivers First Positive Phase 3 Results in Non-Obstructive HCM
Cytokinetics shares fell after reporting the first positive Phase 3 trial results in non-obstructive hypertrophic cardiomyopathy. The market response indicates investors were looking for stronger clinical benefits from MYQORZO, the company's new heart treatment.
CYTOKINETICS · NASDAQ: CYTK
MYQORZO: approval opportunity meets a higher safety bar
Market data: Aug. 28, 2026, 10:08 EDT
Clinical and financial data: Aug. 28 / Aug. 6, 2026
Clinical and financial data: Aug. 28 / Aug. 6, 2026
Implied value lost
≈$515M
Market cap: $9.78B
Volume
962K
Through 10:08 EDT
Analyst target
$109.90
+48.5% vs. quote
ACACIA-HCM efficacy at Week 36
| Endpoint | MYQORZO | Placebo | Net effect | p-value |
|---|---|---|---|---|
| KCCQ-CSS | +11.4 | +8.4 | +3.0 pts | 0.021 |
| Peak VO2 | +0.64 | −0.03 | +0.67 ml/kg/min | 0.003 |
| NYHA class improvement | 41.9% | 27.8% | +14.1 pts | <0.001 |
| NT-proBNP ratio | 0.43 | 1.00 | 0.43 | <0.001 |
517 participants; randomized 1:1. Both primary endpoints met the prespecified 0.025 threshold.
Safety and unresolved outcomes
LVEF below 50%
10.5% MYQORZO vs 0.8% placeboSerious adverse events
20.2% MYQORZO vs 14.7% placeboLeft-atrial volume and time to first cardiovascular event did not reach significance. Two treated patients had serious heart-failure events associated with LVEF below 50%.
Commercial launch signals
$25.3M Q2 product sales1,500 patients dispensed700+ prescribers80%+ paid therapy$23.0M U.S. sales$2.3M Europe salesQ2 product cost was $2.7M. Early inventory and launch timing limit direct run-rate comparisons.
Cash runway versus commercial build
Cash includes $760.1M net proceeds from an 11.34M-share offering. 2026 R&D plus SG&A guidance: $860M–$890M.
Next valuation checkpoints
Q4 2026Planned supplemental FDA application for symptomatic non-obstructive HCM.2027Potential U.S. launch for the expanded indication, subject to approval.Near termInvestors will watch prescription growth, paid-patient conversion and the safety language regulators require.Consensus20 buy, two hold, zero sell ratings; target range $85–$146.
Investor lens: the Phase 3 win expands MYQORZO's possible revenue base, but Friday's decline prices in questions about clinical magnitude, monitoring burden and launch spending.
Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next
Cytokinetics, Incorporated shares rose $2.17, or 3.5%, to $63.54 in the last trading session of 2025, after swinging between $60.93 and $64.43 on volume of about 1.85 million shares. U.S. markets were shut on Thursday for the New Year’s Day holiday. Yahoo Finance
Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing
Cytokinetics, Incorporated shares rose 3.7% to $63.63 in afternoon trading on Wednesday, after touching $64.40 earlier in the session. The stock traded as low as $60.87, while the S&P 500 tracker and Nasdaq 100 fund were both down about 0.4% to 0.5%.
Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes
Cytokinetics, Incorporated surged on Monday, December 22, 2025, extending a sharp rally that followed the company’s first-ever U.S. drug approval. Shares traded around $69.68 in the session, up roughly 11% from the prior close, after reaching an intraday high near $70.86—a move that pushed the biotech to fresh 52-week highs and re-focused Wall Street on the commercial potential of its newly approved heart drug, Myqorzo. Investing.com
Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks
Biotechnology stocks head into the Christmas-shortened trading week with fresh momentum—and plenty for investors to digest—after a dense run of catalysts between December 19 and December 21, 2025. In the span of 48 hours, the sector saw a major rare-disease acquisition, a closely watched FDA approval in cardiology, IPO paperwork from both biotech and medtech, and a sweeping wave of U.S. drug-pricing headlines that could reshape sentiment into 2026. Investopedia+4Reuters+4Reuters+4
Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)
Leading our roundup are several significant scientific and medical breakthroughs. Researchers in New York unveiled a potential “universal” antiviral strategy, reporting compounds that neutralized seven different viruses across multiple families in lab tests gavi.org. By targeting sugar molecules common to many enveloped viruses, the team identified four small molecules that blocked infections by pathogens ranging from coronaviruses to Nipah and Ebola gavi.org. “This is the kind of antiviral tool the world urgently needs. If a new virus emerges tomorrow, we currently have nothing to deploy. These compounds offer the potential to be that first line of defence,” said Dr. Adam Braunschweig of CUNY, who led the study gavi.org. The findings, published in Science Advances, mark an early proof-of-concept for broad-spectrum antivirals, though further work is needed to advance these candidates into animal and human trials. Experts note this approach could be game-changing in future pandemics, filling the gap while vaccines and virus-specific drugs are developed gavi.org.
TechStock² Updates
